新冠疫情时代后的肺纤维化（综述）
Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).
作者信息
Vasarmidi Eirini, Tsitoura Eliza, Spandidos Demetrios A, Tzanakis Nikolaos, Antoniou Katerina M
机构信息
Department of Respiratory Medicine, University General Hospital of Heraklion, Laboratory of Molecular and Cellular Pneumonology, Medical School, University of Crete, 71003 Heraklion, Greece.
Laboratory of Clinical Virology, School of Medicine, University of Crete, 71003 Heraklion, Greece.
出版信息
Exp Ther Med. 2020 Sep;20(3):2557-2560. doi: 10.3892/etm.2020.8980. Epub 2020 Jul 9.
Abstract
The year 2020 is characterized by the COVID-19 pandemic that has resulted in more than half a million deaths in recent months. The high mortality is associated with acute severe respiratory failure that results in ICU admission and intubation. While facing this fatal disease, research and clinical observations need to be carried out in order to evaluate the long-term effects of the COVID-19 acute respiratory distress syndrome (ARDS). Potent clinical and laboratory biomarkers should be studied to be able to predict the subgroup of patients that are going to deteriorate or develop lung fibrosis. The opportunity of personalized medicine is a good way to consider for these patients.
摘要
2020年的特征是新冠疫情大流行，近几个月已导致超过50万人死亡。高死亡率与急性严重呼吸衰竭有关，后者会导致入住重症监护病房并进行插管。在面对这种致命疾病时，需要开展研究和临床观察，以评估新冠急性呼吸窘迫综合征（ARDS）的长期影响。应研究有效的临床和实验室生物标志物，以便能够预测将会病情恶化或发展为肺纤维化的患者亚组。对于这些患者而言，个性化医疗不失为一种值得考虑的好方法。
相似文献
1
Pulmonary fibrosis in the aftermath of the COVID-19 era (Review).新冠疫情时代后的肺纤维化（综述）
Exp Ther Med. 2020 Sep;20(3):2557-2560. doi: 10.3892/etm.2020.8980. Epub 2020 Jul 9.
2
Post-COVID lung fibrosis: The tsunami that will follow the earthquake.新冠后肺纤维化：地震之后的海啸。
Lung India. 2021 Mar;38(Supplement):S41-S47. doi: 10.4103/lungindia.lungindia_818_20.
3
A Case Report of Rapidly Lethal Acute Respiratory Distress Syndrome Secondary to Coronavirus Disease 2019 Viral Pneumonia.一例继发于2019冠状病毒病病毒性肺炎的快速致死性急性呼吸窘迫综合征病例报告。
Cureus. 2020 May 21;12(5):e8228. doi: 10.7759/cureus.8228.
4
5
Systematic review of extracellular vesicle-based treatments for lung injury: are EVs a potential therapy for COVID-19?基于细胞外囊泡治疗肺损伤的系统评价：细胞外囊泡是治疗新型冠状病毒肺炎的潜在疗法吗？
J Extracell Vesicles. 2020 Aug 6;9(1):1795365. doi: 10.1080/20013078.2020.1795365.
6
Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome.重症急性呼吸综合征危重症患者的急性呼吸窘迫综合征
JAMA. 2003 Jul 16;290(3):374-80. doi: 10.1001/jama.290.3.374.
7
Hamman-Rich Syndrome: A Diagnosis of Exclusion in the COVID-19 Pandemic.哈曼-里奇综合征：COVID-19大流行中的排除性诊断。
Cureus. 2020 Aug 19;12(8):e9866. doi: 10.7759/cureus.9866.
8
Post-COVID-19 pulmonary fibrosis: A case series and review of literature.新型冠状病毒肺炎后肺纤维化：病例系列报道及文献综述
J Family Med Prim Care. 2021 May;10(5):2028-2031. doi: 10.4103/jfmpc.jfmpc_2126_20. Epub 2021 May 31.
9
Caring for respiratory disease in India in the COVID era.新冠疫情时代印度的呼吸道疾病护理
Expert Rev Respir Med. 2021 Aug;15(8):959-961. doi: 10.1080/17476348.2021.1924682. Epub 2021 May 13.
10
[The aftermath of the COVID-19 pandemic an opportunity to reform health].[新冠疫情的余波：改革医疗卫生体系的契机]
Bull Acad Natl Med. 2022 Jun;206(6):695-697. doi: 10.1016/j.banm.2022.03.001. Epub 2022 Mar 7.
引用本文的文献
1
Pharmacological Immunomodulation via Collagen-Polyvinylpyrrolidone or Pirfenidone Plays a Role in the Recovery of Patients with Severe COVID-19 Through Similar Mechanisms of Action Involving the JAK/STAT Signalling Pathway: A Pilot Study.通过胶原蛋白-聚乙烯吡咯烷酮或吡非尼酮进行的药理免疫调节通过涉及JAK/STAT信号通路的相似作用机制在重症COVID-19患者的康复中发挥作用：一项初步研究。
Adv Respir Med. 2025 Jul 18;93(4):24. doi: 10.3390/arm93040024.
2
Serum ferritin as a predictive marker of pulmonary fibrosis in post-COVID-19.血清铁蛋白作为新冠后肺纤维化的预测标志物
Qatar Med J. 2025 Jun 9;2025(2):44. doi: 10.5339/qmj.2025.44. eCollection 2025.
3
Integration of pharmacodynamics, network pharmacology and metabolomics to elucidate the effect and mechanism of Jingfang Granule in the treatment of Paraquat induced Pulmonary fibrosis.整合药效学、网络药理学和代谢组学以阐明荆防颗粒治疗百草枯诱导的肺纤维化的作用及机制。
PLoS One. 2025 Feb 18;20(2):e0318246. doi: 10.1371/journal.pone.0318246. eCollection 2025.
4
Surviving COVID-19 and Battling Fibrosis: A Retrospective Cohort Study Across Three Pandemic Waves.从新冠疫情中幸存并对抗纤维化：一项跨越三波疫情的回顾性队列研究
Diagnostics (Basel). 2024 Dec 13;14(24):2811. doi: 10.3390/diagnostics14242811.
5
Pdgfrα stromal cells, a key regulator for tissue homeostasis and dysfunction in distinct organs.血小板衍生生长因子受体α（Pdgfrα）基质细胞是不同器官组织稳态和功能障碍的关键调节因子。
Genes Dis. 2024 Mar 9;12(2):101264. doi: 10.1016/j.gendis.2024.101264. eCollection 2025 Mar.
6
The role of epithelial-mesenchymal transition in pulmonary fibrosis: lessons from idiopathic pulmonary fibrosis and COVID-19.上皮-间充质转化在肺纤维化中的作用：特发性肺纤维化和 COVID-19 的启示。
Cell Commun Signal. 2024 Nov 13;22(1):542. doi: 10.1186/s12964-024-01925-y.
7
Deciphering the age-dependent changes of pulmonary fibroblasts in mice by single-cell transcriptomics.通过单细胞转录组学解析小鼠肺成纤维细胞的年龄依赖性变化。
Front Cell Dev Biol. 2023 Nov 29;11:1287133. doi: 10.3389/fcell.2023.1287133. eCollection 2023.
8
Outcomes of COVID-19 amongst patients with ongoing use of inhaled corticosteroids - a systematic review & meta-analysis.持续使用吸入性糖皮质激素的 COVID-19 患者的预后——一项系统评价与荟萃分析
Infez Med. 2023 Dec 1;31(4):440-448. doi: 10.53854/liim-3104-3. eCollection 2023.
9
Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition.新冠病毒诱导肺纤维化及上皮-间质转化的分子机制
Front Pharmacol. 2023 Aug 3;14:1218059. doi: 10.3389/fphar.2023.1218059. eCollection 2023.
10
Computed tomography chest findings in post-acute COVID-19 lung disease at a South African regional hospital - a descriptive study.南非地区医院急性新冠后肺病的胸部计算机断层扫描结果-描述性研究。
Pan Afr Med J. 2023 Apr 13;44:175. doi: 10.11604/pamj.2023.44.175.39711. eCollection 2023.
本文引用的文献
1
[Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik's Cube solver.[评论] 对抗新型冠状病毒SARS-CoV-2的治疗策略：对魔方解谜者的一项挑战。
Exp Ther Med. 2020 Jul;20(1):147-150. doi: 10.3892/etm.2020.8692. Epub 2020 Apr 28.
2
Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis.吡非尼酮、阿奇霉素和泼尼松龙联合治疗甲型H1N1流感后急性呼吸窘迫综合征肺纤维化
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(1):85-90. doi: 10.36141/svdld.v35i1.6393. Epub 2018 Apr 28.
3
Analysis of thin-section CT in patients with coronavirus disease (COVID-19) after hospital discharge.出院后新型冠状病毒肺炎（COVID-19）患者的薄层 CT 分析。
J Xray Sci Technol. 2020;28(3):383-389. doi: 10.3233/XST-200685.
4
Circulating fibrocytes traffic to the lung in murine acute lung injury and predict outcomes in human acute respiratory distress syndrome: a pilot study.循环成纤维细胞在小鼠急性肺损伤中迁移到肺部，并可预测人类急性呼吸窘迫综合征的结局：一项初步研究。
Mol Med. 2020 May 27;26(1):52. doi: 10.1186/s10020-020-00176-0.
5
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.肺纤维化与 COVID-19：抗纤维化治疗的潜在作用。
Lancet Respir Med. 2020 Aug;8(8):807-815. doi: 10.1016/S2213-2600(20)30225-3. Epub 2020 May 15.
6
Pulmonary fibrosis secondary to COVID-19: a call to arms?新型冠状病毒肺炎继发的肺纤维化：吹响战斗的号角？
Lancet Respir Med. 2020 Aug;8(8):750-752. doi: 10.1016/S2213-2600(20)30222-8. Epub 2020 May 15.
7
Early CT features and temporal lung changes in COVID-19 pneumonia in Wuhan, China.中国武汉 COVID-19 肺炎的早期 CT 特征和时间性肺部变化。
Eur J Radiol. 2020 Jul;128:109017. doi: 10.1016/j.ejrad.2020.109017. Epub 2020 Apr 19.
8
Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.COVID-19 患者出院时的肺功能异常。
Eur Respir J. 2020 Jun 18;55(6). doi: 10.1183/13993003.01217-2020. Print 2020 Jun.
9
Complement as a target in COVID-19?补体作为 COVID-19 的靶点？
Nat Rev Immunol. 2020 Jun;20(6):343-344. doi: 10.1038/s41577-020-0320-7. Epub 2020 Apr 23.
10
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure.COVID-19 患者严重呼吸衰竭的复杂免疫失调。
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. doi: 10.1016/j.chom.2020.04.009. Epub 2020 Apr 21.
Zotero 插件